Clinical Performance Evaluation and Cost-Effectiveness Analysis of miLab platform for Supporting Malaria Control in Target Countries

Noul Inc, a South Korean start-up, has developed the miLab(TM) platform, which allows automated sample preparation to imaging and AI analysis of small amounts of blood samples. The platform is of potential high interested for malaria control, namely malaria diagnostics in low- and middle-income countries, as malaria remains a major cause of morbidity and mortality in large parts of Africa. Information on cost, cost-effectiveness and impact is therefore essential to validate the use of the miLab platform and scale-up this diagnostic device in routine health service delivery in low- and middle-income African countries.

The economic evaluation includes a cost analysis and modelled cost-effectiveness using direct health system costs, assessing financial and economic costs. The main interest is to assess the full and incremental costs of the new technology miLab from Noul Inc. compared to the current routine malaria diagnostic in the field. The impact evaluation will also assess whether and how the use of miLab contributes to an improved malaria case detection workflow in two target countries. The method will be compared to manual staining and reading of blood smears under the microscope (the current gold standard) and with rapid diagnostic tests (RDT).

Involved Regions: Africa
Involved Countries: Nigeria, Ghana


Kaspar Wyss

Kaspar Wyss, Professor, PhD, MPH
Head of Department, Deputy Director


Project Facts